Surgery Today

, Volume 48, Issue 2, pp 223–228 | Cite as

Serum calcitonin reference values for calcium stimulation tests by electrochemiluminescence immunoassay in Japanese men with non-medullary thyroid carcinoma

  • Minoru Kihara
  • Akira Miyauchi
  • Takumi Kudo
  • Mitsuyoshi Hirokawa
  • Akihiro Miya
Original Article



Calcitonin is the most sensitive tumor marker of medullary thyroid carcinoma (MTC) and a calcium stimulation test is used to improve this sensitivity. In Japan, the electrochemiluminescence immunoassay (ECLIA) is currently the only test performed to measure serum calcitonin. There is a gender difference in the reference value of serum calcitonin; however, a reference upper limit for use with ECLIA has been reported only for women, but not for men.


We conducted the calcium stimulation test using ECLIA in 21 men with non-medullary thyroid carcinoma (non-MTC), before and after total thyroidectomy.


Preoperatively, the basal calcitonin values were within normal limits in all patients. They increased to a mean value of 37.6 pg/mL after calcium stimulation, and we calculated that the reference upper limit was 83.7 pg/mL. The stimulation test results after total thyroidectomy showed undetectable basal and stimulated calcitonin values in every patient (<0.5 pg/mL).


To our knowledge, this is the first study to calculate reference values for this stimulation test using an ECLIA in men with non-MTC. We propose that men can be regarded as biochemically cured or as having normal serum calcitonin values when the stimulated calcitonin values obtained by ECLIA are <83.7 pg/mL before and <0.5 pg/mL after total thyroidectomy.


Calcitonin Calcium stimulation Medullary thyroid carcinoma Electrochemiluminescence immunoassay (ECLIA) Male 


Compliance with ethical standards

Conflict of interest

We have no conflict of interest to disclose.


  1. 1.
    Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European Thyroid Association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J. 2013;1:216–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Bugalho MJM, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 2005;91:56–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Rodding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid. 2000;10:919–22.CrossRefGoogle Scholar
  5. 5.
    Hamy A, Pessaux P, Mirallie E, Mucci-Hennekinne S, Gibelin H, Mor-Martinez C, et al. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Sur Oncol. 2005;31:774–7.CrossRefGoogle Scholar
  6. 6.
    Kudo T, Miyauchi A, Ito Y, Yabuta T, Inoue H, Higashiyama T, et al. Serum calcitonin levels with calcium loading tests before and after total thyroidectomy in patients with thyroid diseases other than medullary thyroid carcinoma. Endocr J. 2011;58:217–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Lifante JC, Blanchard C, Mirallié E, David A, Peix JL. Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations. World J Surg. 2014;38:576–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab. 2014;99:1656–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Lorenz K, Elwerr M, Machens A, Abuazab M, Holzhausen HJ, Dralle H. Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin. Langenbecks Arch Surg. 2013;398:403–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Thiem U, Marculescu R, Cejka D, Gessl A, Borchhardt K. Low-dose calcium versus pentagastrin for stimulation of calcitonin in chronic hemodialysis patients: a pilot study. J Clin Endocrinol Metab. 2014;99:4704–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Fugazzola L. Stimulated calcitonin cut-offs by different tests. Eur Thyroid J. 2013;2:49–56.PubMedPubMedCentralGoogle Scholar
  12. 12.
    De Crea C, Raffaelli M, Milano V, Carrozza C, Zuppi C, Bellantone R, et al. Intraoperative high-dose calcium stimulation test in patients with sporadic medullary thyroid carcinoma is highly accurate in predicting lateral neck metastases. Surgery. 2016;159:70–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Vainas I, Marthopoulos A, Chrisoulidou A, Raptou K, Tziomalos K, Pazaitou-Panayiotou K. Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis. Hippokratia. 2013;17:246–51.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Papadakis G, Keramidas I, Triantafillou E, Kanouta F, Pappa T, Kaltzidou V, et al. Association of basal and calcium-stimulated calcitonin levels with pathological findings after total thyroidectomy. Anticancer Res. 2015;35:4251–8.PubMedGoogle Scholar
  15. 15.
    Ito Y, Miyauchi A, Yabuta T, Fukushima M, Inoue H, Tomoda C, et al. Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution. World J Surg. 2009;33:58–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Colombo C, Verga U, Mian C, Ferrero S, Perrino M, Vicentini L, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab. 2012;97:905–13.CrossRefPubMedGoogle Scholar
  17. 17.
    Giovanella L. Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. Exp Clin Endocrinol Diabetes. 2012;120:169–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Bümming P, Ahlman H, Nilsson B, Nilsson O, Wängberg B, Jansson S. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma? Langenbecks Arch Surg. 2008;393:699–703.CrossRefPubMedGoogle Scholar
  19. 19.
    Ito Y, Miyauchi A, Kihara M, Kudo T, Miya A. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients’ carcinoma death. Endocr J. 2016;63:663–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Kihara M, Miyauchi A, Kudo T, Hirokawa M, Miya A. Reference values of serum calcitonin with calcium stimulation tests by electrochemiluminescence immunoassay before/after total thyroidectomy in Japanese patients with thyroid diseases other than medullary thyroid carcinoma. Endocr J. 2016;63:627–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Ichihara K, Boyd JC, IFCC Committee on Reference Intervals and Decision Limits (C-RIDL). An appraisal of statistical procedures used in derivation of reference intervals. Clin Chem Lab Med. 2010;48:1537–51.CrossRefPubMedGoogle Scholar
  22. 22.
    de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf). 2006;65:729–36.CrossRefGoogle Scholar
  23. 23.
    Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537–42.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Rowland KJ, Jin LX, Moley JF. Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol. 2015;22:96–102.CrossRefPubMedGoogle Scholar
  26. 26.
    Milone F, Ramundo V, Chiofalo MG, Severino R, Paciolla I, Pezzullo L, et al. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol. 2010;73:85–8.Google Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  • Minoru Kihara
    • 1
  • Akira Miyauchi
    • 1
  • Takumi Kudo
    • 2
  • Mitsuyoshi Hirokawa
    • 3
  • Akihiro Miya
    • 1
  1. 1.Department of SurgeryKuma HospitalKobeJapan
  2. 2.Department of Internal MedicineKuma HospitalKobeJapan
  3. 3.Department of Diagnostic PathologyKuma HospitalKobeJapan

Personalised recommendations